Neurol. praxi. 2023;24(1):60-64 | DOI: 10.36290/neu.2023.012

Autoimmune disease with positivity of anti­‑CASPR2 antibodies - a case report

MUDr. Lubomír Jurák, Ph.D.1, 2, 3, MUDr. Zuzana Eichlová4, MUDr. Eva Řeháčková4, MUDr. Martin Jíra4, MUDr. David Krýsl, Ph.D.5, MUDr. Martin Elišák, Ph.D.5, prof. MUDr. Petr Suchomel, Ph.D.1
1 Neurochirurgické oddělení, Krajská nemocnice Liberec, a. s., Liberec
2 Neurochirurgická klinika LF UP a FN Olomouc
3 Fakulta zdravotnických studií, Technická univerzita v Liberci
4 Neurologické oddělení, Krajská nemocnice Liberec, a. s., Liberec
5 Neurologická klinika 2. LF UK a FN Motol, Praha

Autoimmune disease associated with anti-CASPR2 antibodies is a relatively rare neurological illness characterized by the presence of anti-CASPR2 antibodies in serum and/or CSF. It manifests with a variety of symptoms - from the central nervous system (cognitive impairment, epilepsy and cerebellar symptoms), from the peripheral nervous system (peripheral nerve hyperexcitability and neuropathic pain), and from the autonomic nervous system (autonomic dysfunction, insomnia and weight loss).

Case report: The 61-year-old patient was admitted to the intensive care unit of our neurological department with myoclonic abdominal muscle twitching with intermittent generalization and right upper limb myoclonus, associated with behavioral change, cognitive deterioration, intermittent disorientation and aggression, bulbar syndrome, dysarthria, and dysautonomia (hypersalivation, bronchial hypersecretion, and circulatory instability). Due to progressive hypercapnia and loss of consciousness, the patient had to be intubated and connected to artificial pulmonary ventilation. EMG investigation demonstrated axonal motor polyneuropathy of both upper and lower limbs. Several unspecific gliotic lesions located in the white matter adjacent to the left cerebral ventricle were described on the brain MRI. Significant anti-CASPR2 antibody positivity was found both in serum and cerebrospinal fluid. Treatment with i.v. methylprednisolone and intravenous immunoglobulins was applied. With this treatment, the patient's neurological status gradually improved to the ability of verticalization. However, his cachectization, which was already present on admission, progressed despite the maximal effort in nutrition therapy. Also, repeated episodes of respiratory insufficiency resulting in transitory impairment of consciousness occurred. One such episode resulted in cardiac arrest followed by successful cardiopulmonary resuscitation. However, myoclonic jerks reappeared afterward and the patient's overall condition worsened. At this stage, it was decided not to further escalate and extend the treatment. Palliative treatment was commenced. The patient died during the following episode of respiratory failure. Comment: This case report of a patient with autoimmune disease associated with anti-CASPR2 antibodies highlights its multiple and often disease-unspecific clinical symptoms on the one hand, and on the other, its severe and ultimately fatal clinical course despite the initial effect of immunotherapy. Early diagnosis and early and aggressive immunomodulatory treatment are crucial in patients with this disorder.

Keywords: CASPR2 antibodies, autoimmune disease, limbic encephalitis, immunosuppressive therapy, plasmapheresis.

Accepted: February 28, 2023; Published: March 3, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jurák L, Eichlová Z, Řeháčková E, Jíra M, Krýsl D, Elišák M, Suchomel P. Autoimmune disease with positivity of anti­‑CASPR2 antibodies - a case report. Neurol. praxi. 2023;24(1):60-64. doi: 10.36290/neu.2023.012.
Download citation

References

  1. Abou­‑Zeid E, Boursoulian LJ, Metzer WS, Gundogdu B. Morvan syndrome: a case report and review of the literature. J Clin Neuromuscul, DiS. 2012;13(4):214-27. doi: 10.1097/CND.0b013e31822b1977. Go to original source... Go to PubMed...
  2. Boronat A, Gelfand JM, Gresa­‑Arribas N, et al. Encephalitis and antibodies to dipeptidyl­‑peptidase­‑like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol. 2013;73(1):120-8. doi: 10.1002/ana.23756. Go to original source... Go to PubMed...
  3. Elišák M, Marusič P. Kdy v klinické praxi myslet na vzácná autoimunitní onemocnění centrálního nervového systému. Neurol. praxi. 2015;16(6):340-344.
  4. Feyissa AM, López Chiriboga AS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e353. doi: 10.1212/NXI.0000000000000353. Go to original source... Go to PubMed...
  5. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734-48. doi: 10.1093/brain/awq213. Go to original source... Go to PubMed...
  6. Joubert B, Saint-Martin M, Noraz N, et al. Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures. JAMA Neurol. 2016;73(9):1115-24. doi: 10.1001/jamaneurol.2016.1585. Go to original source... Go to PubMed...
  7. Junkerová J, Novák V. Neuromyotonie. Neurol. praxi. 2013;14(2):105-108.
  8. Krogias C, Hoepner R, Müller A, et al. Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab. JAMA Neurol. 2013;70(8):1056-9. doi: 10.1001/jamaneurol.2013.143. Go to original source... Go to PubMed...
  9. Krýsl D. Autoimunitní encefalitidy. Neurol. praxi. 2015;16(6):317-323.
  10. Krýsl D, Elišák M. Autoimunitní encefalitidy. Cesk Slov Neurol N. 2015;78/111(1):7-23. Go to original source...
  11. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776-85. doi: 10.1016/S1474-4422(10)70137-X. Go to original source... Go to PubMed...
  12. Latta J, Ehler E, Zámečník J. Získaná neuromyotonie s nevelkými centrálními příznaky s průkazem protilátek proti napěťově řízeným kaliovým kanálům - kazuistika. Cesk Slov Neurol N. 2009;72/105(4):373-377.
  13. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9(1):67-76. doi: 10.1016/S1474-4422(09)70324-2. Go to original source... Go to PubMed...
  14. Majerová V, Roth J, Waishaupt J, et al. Limbická encefalitida - dvě kazuistiky. Cesk Slov Neurol N. 2011;74/107(3):335-338.
  15. Morvan A. De la chorée fibrillaire. Gazette Hebdomadaire de médecine et de Chirurgie. 1890;27(15):173-176/(16);186-189/(17):200-202.
  16. Paterson RW, Zandi MS, Armstrong R, Vincent A, Schott JM. Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry. 2014;85(6):625-30. doi: 10.1136/jnnp-2013-305218. Go to original source... Go to PubMed...
  17. Shin YW, Lee ST, Park KI, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2017;11:1756285617722347. doi: 10.1177/1756285617722347. Go to original source... Go to PubMed...
  18. Su Y, Cui L, Zhu M, Liang Y, Zhang Y. Progressive Encephalomyelitis With Rigidity and Myoclonus With Thymoma: A Case Report and Literature Review. Front Neurol. 2020;11:1017. doi: 10.3389/fneur.2020.01017. Go to original source... Go to PubMed...
  19. van Sonderen A, Ariño H, Petit-Pedrol M, et al. The clinical spectrum of CASPR2 antibody-associated disease. Neurology. 2016;87(5):521-8. doi: 10.1212/WNL.0000000000002917. Go to original source... Go to PubMed...
  20. Zborníková P, Krasulová E, Bušek P, et al. Autoimunitní limbická encefalitida asociovaná s LGI1 protilátkami. Neurol. praxi. 2012;13(6):343-346.




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.